Literature DB >> 11180937

Synthesis and intramitochondrial levels of valproyl-coenzyme A metabolites.

M F Silva1, J P Ruiter, L IJlst, P Allers, H J ten Brink, C Jakobs, M Duran, I Tavares de Almeida, R J Wanders.   

Abstract

A number of valproate adverse reactions are due to its interference with several metabolic pathways, including that of fatty acid oxidation. In order to resolve which mitochondrial enzymes of fatty acid oxidation are inhibited by which VPA intermediates we have developed methods to synthesize their CoA ester forms. This paper describes the synthesis of VPA acyl-CoA ester metabolites as well as data on the fate of VPA in rat liver mitochondria. Valproyl-CoA, Delta2-valproyl-CoA, and 3-OH-valproyl-CoA were obtained through chemical synthesis. 3-Keto-valproyl-CoA was prepared by a novel enzymatic procedure followed by a combination of solid-phase extraction and preparative HPLC purification. This approach proved to be efficient in obtaining all the beta-oxidation intermediates of valproyl-CoA. The synthetic standards were used for the determination of intramitochondrial concentrations of valproyl-CoA, Delta2-valproyl-CoA, 3-OH-valproyl-CoA, and 3-keto-valproyl-CoA by HPLC. These levels were determined after incubation of intact rat liver mitochondria with VPA under conditions of state 3 and state 4 respiration. The results show that valproyl-CoA and to a much lesser extent 3-keto-valproyl-CoA are the main metabolites of VPA in mitochondria. This information will be of great use in resolving the mechanisms involved in the inhibition of mitochondrial processes like fatty acid oxidation by VPA.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11180937     DOI: 10.1006/abio.2000.4947

Source DB:  PubMed          Journal:  Anal Biochem        ISSN: 0003-2697            Impact factor:   3.365


  17 in total

1.  Valproic acid selectively inhibits conversion of arachidonic acid to arachidonoyl-CoA by brain microsomal long-chain fatty acyl-CoA synthetases: relevance to bipolar disorder.

Authors:  Richard P Bazinet; Margaret T Weis; Stanley I Rapoport; Thad A Rosenberger
Journal:  Psychopharmacology (Berl)       Date:  2005-12-13       Impact factor: 4.530

2.  Valproic Acid and Hepatic Steatosis: A Possible Link? About a Case Report.

Authors:  Leila Mnif; Rim Sellami; Jawaher Masmoudi
Journal:  Psychopharmacol Bull       Date:  2016-08-15

3.  Inhibition of 3-methylcrotonyl-CoA carboxylase explains the increased excretion of 3-hydroxyisovaleric acid in valproate-treated patients.

Authors:  Paula B M Luís; Jos P Ruiter; Lodewijk IJlst; Luísa Diogo; Paula Garcia; Isabel Tavares de Almeida; Marinus Duran; Ronald J Wanders; Margarida F B Silva
Journal:  J Inherit Metab Dis       Date:  2011-12-22       Impact factor: 4.982

4.  Valproyl-CoA inhibits the activity of ATP- and GTP-dependent succinate:CoA ligases.

Authors:  Paula B M Luís; Jos Ruiter; Lodewijk IJlst; Isabel Tavares de Almeida; Marinus Duran; Ronald J A Wanders; Margarida F B Silva
Journal:  J Inherit Metab Dis       Date:  2013-10-24       Impact factor: 4.982

5.  Role of isovaleryl-CoA dehydrogenase and short branched-chain acyl-CoA dehydrogenase in the metabolism of valproic acid: implications for the branched-chain amino acid oxidation pathway.

Authors:  Paula B M Luís; Jos P N Ruiter; Lodewijk Ijlst; Isabel Tavares de Almeida; Marinus Duran; Al-Walid Mohsen; Jerry Vockley; Ronald J A Wanders; Margarida F B Silva
Journal:  Drug Metab Dispos       Date:  2011-03-23       Impact factor: 3.922

6.  Valproyl-CoA and esterified valproic acid are not found in brains of rats treated with valproic acid, but the brain concentrations of CoA and acetyl-CoA are altered.

Authors:  Joseph Deutsch; Stanley I Rapoport; Thad A Rosenberger
Journal:  Neurochem Res       Date:  2003-06       Impact factor: 3.996

7.  Molecular cloning and heterologous expression of the C-13 phenylpropanoid side chain-CoA acyltransferase that functions in Taxol biosynthesis.

Authors:  Kevin Walker; Shingo Fujisaki; Robert Long; Rodney Croteau
Journal:  Proc Natl Acad Sci U S A       Date:  2002-09-13       Impact factor: 11.205

8.  Glucose metabolism as a target of histone deacetylase inhibitors.

Authors:  Suzanne E Wardell; Olga R Ilkayeva; Heather L Wieman; Daniel E Frigo; Jeffrey C Rathmell; Christopher B Newgard; Donald P McDonnell
Journal:  Mol Endocrinol       Date:  2008-12-23

9.  Investigation of the drug-drug interaction between alpha-lipoic acid and valproate via mitochondrial beta-oxidation.

Authors:  Lee Cheng Phua; Lee Sun New; Catherine W Goh; Aveline H Neo; Edward R Browne; Eric C Y Chan
Journal:  Pharm Res       Date:  2008-07-18       Impact factor: 4.200

Review 10.  Valproic acid metabolism and its effects on mitochondrial fatty acid oxidation: a review.

Authors:  M F B Silva; C C P Aires; P B M Luis; J P N Ruiter; L IJlst; M Duran; R J A Wanders; I Tavares de Almeida
Journal:  J Inherit Metab Dis       Date:  2008-04-04       Impact factor: 4.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.